Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

C1orf56 Inhibitors

C1orf56 inhibitors encompass a spectrum of chemical compounds that reduce the functional activity of C1orf56 through various cellular signaling pathways. Protein kinase activity, which may regulate C1orf56 through phosphorylation, is targeted by Staurosporine, a broad-spectrum inhibitor that decreases kinase activity, potentially affecting the phosphorylation state and function of C1orf56. The PI3K/Akt pathway, often associated with cell survival and growth, is another target; both Wortmannin and LY 294002 serve as PI3K inhibitors, which could decrease C1orf56 activity if it is linked to this pathway. Similarly, Rapamycin, an mTOR pathway inhibitor, might reduce C1orf56 activity associated with cell growth or autophagy. Inhibitors like PD 98059 and U0126 target the MAPK/ERK pathway and could consequently reduce C1orf56 activity if it is regulated through this signaling cascade.

Further modulation of C1orf56 activity is achieved through the inhibition of other signaling pathways. SB 203580 specifically inhibits the p38 MAPK pathway, potentially reducing C1orf56 activity in stress response signaling. JNK pathway, involved in apoptosis and cell differentiation, is targeted by SP600125, which could also lead to decreased C1orf56 function. Bortezomib, by inhibiting proteasome activity, may indirectly lower C1orf56 levels by stabilizing proteins that suppress its expression or function. Cyclopamine and Chelerythrine diminish the Hedgehog signaling and PKC pathways, respectively, which could lead to reduced C1orf56 activity if the protein is involved in these pathways. Lastly, Trichostatin A, by inhibiting histone deacetylases, could affect chromatin remodeling and decrease C1orf56 activity if its expression is modulated by acetylation status. Collectively, these inhibitors operate through distinct but interconnected biochemical pathways, converging on the diminution of C1orf56 activity without directly altering its transcription or translation, but rather by influencing the cellular processes it is involved with.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A potent protein kinase inhibitor, Staurosporine diminishes broad-spectrum protein kinase activity, which could indirectly diminish C1orf56 activity if C1orf56 is regulated by phosphorylation.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a PI3K inhibitor that leads to the inhibition of the PI3K/Akt pathway, potentially diminishing C1orf56 function if C1orf56 is involved in cell survival or growth signals mediated by this pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY 294002 is another PI3K inhibitor, and it could indirectly diminish C1orf56 activity by inhibiting the PI3K/Akt pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor, Rapamycin reduces the activity of the mTOR pathway, which might diminish C1orf56 if its function is tied to cell growth or autophagy processes regulated by mTOR.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

An MEK inhibitor, PD 98059 inhibits the MAPK/ERK pathway, which could lead to reduced activity of C1orf56 if it is regulated through this signaling pathway.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Another MEK inhibitor, U0126 could diminish the functional activity of C1orf56 by inhibiting the MAPK/ERK pathway, assuming C1orf56 is involved in this pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor, SB 203580 could reduce C1orf56 activity by inhibiting the p38 MAPK pathway, should C1orf56 function be associated with stress response signals.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, SP600125 could lead to diminished activity of C1orf56 if C1orf56 is involved in the apoptotic or cell differentiation processes regulated by the JNK pathway.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor, Bortezomib might reduce C1orf56 levels by preventing the degradation of regulatory proteins that suppress C1orf56 expression or function.

Cyclopamine

4449-51-8sc-200929
sc-200929A
1 mg
5 mg
$92.00
$204.00
19
(1)

A Hedgehog signaling pathway inhibitor, Cyclopamine could diminish C1orf56 activity if C1orf56 is part of the signaling cascade or is regulated by it.